Skip to content
Toggle main navigation
PURPOSE logo
PURPOSE logo
  • Home
  • Events
  • Opportunities
  • News & Publications
  • T90/R90 HEAL Pain Cohort Program
  • Mobile App
  • About
  • Exhibit
  • Affiliate Networks
    • Music4Pain (U24)
    • ENSEMBLE Network (U24)
    • Pain Research Forum (PRF)
    • ForceNET (U24)
    • NeuronS_MATTR (U24)
    • SPINEWORK Network (U24)
    Log in
    Request to Join

    News & Publications

    Do you have news or publications to share with the PURPOSE Network? Submit your news below.

    Submit Your News or Publication
    All
    Acquired Cognitive Impairment
    Acupuncture
    Addiction
    Ageing
    Alcohol Use / Alcohol Use Disorder (AUD)
    Analgesics
    Analgesics, Topical
    Anatomy
    Anesthesia, General
    Anesthesia, Intravenous regional
    Anesthesia, Local
    Anesthesia, Spinal
    Animal Models
    Anxiety
    Arthritis, Rheumatoid
    See all

    Highlighted News

    Results (6)

    Myotonic Muscle Activity Drives a Persistent Pain State Responsive to NaV1.8-directed Analgesics

    Myotonic Muscle Activity Drives a Persistent Pain State Responsive to NaV1.8-directed Analgesics

    J Clin Invest. 2026 Sep 8:e198055. doi: 10.1172/JCI198055. Online ahead of print.ABSTRACTPain is a common and disabling feature of myotonic disorders, yet its biological basis remains poorly understood and no targeted analgesic therapies currently exist. Here, we demonstrate that skeletal muscle hyperexcitability is sufficient to initiate a persistent pain state independent of inflammation, nerve
    September 8, 2026
    Phase 2b Trial of a Na(V)1.8 Inhibitor for Acute Pain

    Phase 2b Trial of a Na(V)1.8 Inhibitor for Acute Pain

    N Engl J Med. 2026 Jul 30;395(5):454-464. doi: 10.1056/NEJMoa2602910.ABSTRACTBACKGROUND: Nav1.8, a voltage-gated sodium channel expressed in the peripheral nervous system, has a critical role in pain signaling. Previous trials of NaV1.8 inhibitors have shown effectiveness in reducing postoperative pain.METHODS: We conducted a phase 2b, double-blind, randomized, placebo-controlled trial to evaluate
    August 6, 2026
    A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets

    A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets

    Front Oncol. 2026 May 19;16:1795684. doi: 10.3389/fonc.2026.1795684. eCollection 2026.ABSTRACTBACKGROUND: Despite a growing volume of clinical research, cancer pain management remains dependent on opioid-centric paradigms with few therapeutic breakthroughs. To identify innovation gaps and guide future research, a systematic evaluation of the global clinical trial landscape is imperative.METHODS: W
    June 4, 2026
    Targeting Supramolecular Active Complexes of Na(v)1.7/Na(v)1.8 to Relieve Chronic Neuropathic Pain

    Targeting Supramolecular Active Complexes of Na(v)1.7/Na(v)1.8 to Relieve Chronic Neuropathic Pain

    Adv Sci (Weinh). 2026 May 20:e22185. doi: 10.1002/advs.202522185. Online ahead of print.ABSTRACTNeuropathic pain (NP) affects 7%-10% of population, with current treatments often proving inadequate. Here we show that Nav1.7 and Nav1.8 form supramolecular active complexes (SMACs) with polygonal lattice structure in dorsal root ganglion (DRG) neurons of mouse models and patients with severe chronic N
    May 20, 2026
    Discovery of MK-5661, a Once-Daily Oral Na(V)1.8 Inhibitor for the Treatment of Pain

    Discovery of MK-5661, a Once-Daily Oral Na(V)1.8 Inhibitor for the Treatment of Pain

    ACS Med Chem Lett. 2026 Apr 24;17(5):1189-1194. doi: 10.1021/acsmedchemlett.6c00132. eCollection 2026 May 14.ABSTRACTNaV1.8 is a key mediator of peripheral nociceptive signaling and an attractive nonopioid target for pain therapeutics. We report the discovery of MK 5661, a potent, selective, and orally bioavailable NaV1.8 inhibitor amenable to once-daily dosing. Optimization of an initial lead, gu
    May 20, 2026
    EXPRESS: Metformin Exhibits Analgesic Activity in Neuronal Cell Models and CFA-Induced Inflammatory Pain in Mice

    EXPRESS: Metformin Exhibits Analgesic Activity in Neuronal Cell Models and CFA-Induced Inflammatory Pain in Mice

    Mol Pain. 2026 May 14:17448069261452893. doi: 10.1177/17448069261452893. Online ahead of print.ABSTRACTInflammatory pain is mediated by complex interactions between immune signaling and sensory neurons, with prostaglandin E2-dependent pathways playing a central role in nociceptive sensitization. Metformin, a first-line antidiabetic drug, has emerged as a potential non-opioid analgesic due to its p
    May 14, 2026
    Contact
    Neurovations Education
    [email protected]

    United States

    PURPOSE@PainResearchers.com
    707-260-0848
    Links
    • NIH HEAL Initiative
    • Research in Pain Management